Management of severe pulmonary arterial hypertension Source: Eur Respir Rev 2010 19: 279-287 Year: 2010
Effect of sildenafil on exercise ability of patients with World Health Organization functional class II pulmonary arterial hypertension Source: Annual Congress 2009 - Treatment of airways disease Year: 2009
Pulmonary hypertension: diagnosis, differential diagnosis and pitfalls Source: Eur Respir Mon 2012; 57: 17-25 Year: 2012
Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment Source: Eur Respir J 2015; 46: 1461-1470 Year: 2015
Treat-to-target strategies in pulmonary arterial hypertension: the importance of using multiple goals Source: Eur Respir Rev 2010 19: 272-278 Year: 2010
The World Health Organization global aDSM database: generating evidence on the safety of new treatment regimens for drug-resistant tuberculosis Source: Eur Respir J, 51 (3) 1701643; 10.1183/13993003.01643-2017 Year: 2018
The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension Source: Eur Respir J 2012; 39: 589-596 Year: 2012
Incorporating therapeutic drug monitoring into the World Health Organization hierarchy of tuberculosis diagnostics Source: Eur Respir J 2016; 47:1867-1869 Year: 2016
Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension Source: Eur Respir J 2004; 23: 321-326 Year: 2004
Illicit drug use and pulmonary arterial hypertension: Not so frequent Source: International Congress 2016 – Clinic of pulmonary hypertension Year: 2016
Early intervention in pulmonary arterial hypertension associated with systemic sclerosis: an essential component of disease management Source: Eur Respir Rev 2010 19: 314-320 Year: 2010
World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update Source: Eur Respir J , 49 (3) 1602308; DOI: 10.1183/13993003.02308-2016 Year: 2017
Pulmonary hypertension associated with benfluorex exposure Source: Eur Respir J 2012; 40: 1164-1172 Year: 2012
World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update Source: Eur Respir J, 57 (6) 2003300; 10.1183/13993003.03300-2020 Year: 2021
The effectiveness of pulmonary TB treatment in patients with organic liver diseases, depending on the way of administration of anti-TB drugs Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe Year: 2016
New definitions of extensively drug resistant tuberculosis: update from the World Health Organization Source: Virtual Congress 2021 – Advances in treatment and management of tuberculosis and nontuberculous mycobacterial disease Year: 2021
Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation Source: Eur Respir J 2003; 22: 560-562 Year: 2003
Pulmonary arterial hypertension in patients with HIV infection Source: Eur Respir Mon 2012; 57: 82-93 Year: 2012
Pulmonary complications in intravenous drug users with and without human immunodeficiency virus co-infection. Source: International Congress 2019 – Pleural infection and complicated pneumonia Year: 2019